This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Bortezomib for Injection (2016-03-18)

Starting date:
March 18, 2016
Posting date:
April 8, 2016
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-57860

Affected Products

Bortezomib for Injection

Reason

Potential for presence of particulate matter (glass) in this lot.

Depth of distribution

Wholesalers, hospitals - Quebec, British Columbia, Saskatchewan, Manitoba, Ontario, Newfoundland and Labrador

Affected products

Bortezomib for Injection

DIN, NPN, DIN-HIM
DIN 02423405
Dosage form

Powder for solution

Strength

3.5 mg/vial

Lot or serial number

1600615

Companies
Recalling Firm
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
Marketing Authorization Holder
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA

Date modified: